Drug Firm Zydus Cadila OnSaturday Said It Has ReceivedApproval From The Us HealthRegulator To Market DecitabineInjection, Used To Treat CertainTypes Of Cancers, In TheAmerican Market. The CompanyHas Received Final Approval FromThe Us Food And DrugAdministration (Usfda) ToDecitabine For Injection In TheStrength Of 50 Mg/Vial Single-Https://Health.Economictimes.Indiatimes.Com/News/Pharma/Zydus-Cadila-Gets-Usfda-Nod-To-Market-Generic-Cancer-Drug-In-Us/87818957 2/9Importance Of FinancialPlanning For HealthcareIn The Light Of TheNo Scientific Evidence InCountry Underlines NeedFor Covid-19 BoosterSun Pharma Recalls Over1.10 Lakh Bottles OfGeneric Drug In UsCovaxin Offers ProtectionAgainst Multiple Variants:StudyPharma Zydus Cadila Usfda Us Pharma Firms Health News Generic DrugsDose Vial, Zydus Cadila Said In A Statement.Decitabine Is Used To Treat Myelodysplastic Syndromes, Certain Types Of Blood OrBone Marrow Cancer.The Drug Will Be Manufactured At The Group'S Injectables Manufacturing Facility, TheDrug Maker Said.The Zydus Group Now Has 326 Approvals And Has So Far Filed Over 400Abbreviated New Drug Applications (Andas) Since The Commencement Of The FilingProcess In 2003-04, It Added.
